Logo

AstraZeneca Signs an Agreement with ArcherDX for Utilizing Personalized Cancer Assays to Detect MRD in Patients with Early-Stage Non-Small Cell Lung Cancer

Share this

AstraZeneca Signs an Agreement with ArcherDX for Utilizing Personalized Cancer Assays to Detect MRD in Patients with Early-Stage Non-Small Cell Lung Cancer

Shots:

  • AstraZeneca will utilize ArcherDX’s personalized assay in P-III MERMAID-1 study assessing the effect of adjuvant treatment with Imfinzi (durvalumab) + CT vs CT as monothx. in ~330 patients with resected (Stage II-III) NSCLC who have undergone complete resection of the primary tumor
  • The 1EPs is DFS for patients showing MRD- which will be tested using personalized ctDNA assay based on whole-exome sequencing of patient samples.
  • ArcherDX will perform whole-exome sequencing of samples of patients with NSCLC and generate personalized ctDNA assays to test MRD that remains after a patient’s surgery. The ongoing development of assays is informed by the TRACERx study- funded by Cancer Research UK and led by UCL and the Francis Crick Institute

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: Yahoo Finance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions